Lakeshore Biopharma (LSB) Short Interest Ratio & Short Volume

Short interest is the volume of Lakeshore Biopharma shares that have been sold short but have not yet been covered or closed out. As of May 31st, traders have sold 3,900 shares of LSB short. 0.12% of Lakeshore Biopharma's shares are currently sold short. Learn More on Lakeshore Biopharma's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.12% of Lakeshore Biopharma's floating shares are currently sold short.

Lakeshore Biopharma saw a increase in short interest during the month of May. As of May 31st, there was short interest totaling 3,900 shares, an increase of 39.3% from the previous total of 2,800 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Lakeshore Biopharma currently has issued a total of 9,306,000 shares. Some of Lakeshore Biopharma's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Lakeshore Biopharma currently has a public float of 3,300,000 shares.

0.12% of Lakeshore Biopharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Lakeshore Biopharma: SCYNEXIS, Inc. (1.74%), Kezar Life Sciences, Inc. (0.79%), Rani Therapeutics Holdings, Inc. (13.65%), China SXT Pharmaceuticals, Inc. (3.52%), Tempest Therapeutics, Inc. (3.30%), Coeptis Therapeutics Holdings, Inc. (0.92%), FibroGen, Inc. (3.76%), Pulmatrix, Inc. (0.60%), KALA BIO, Inc. (5.71%), Marinus Pharmaceuticals, Inc. (3.95%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($64.96 billion), Invesco QQQ ($27.88 billion), iShares Russell 2000 ETF ($19.94 billion), iShares 20+ Year Treasury Bond ETF ($9.69 billion), Strategy Incorporated ($8.58 billion), SPDR S&P Biotech ETF ($5.72 billion), Invesco S&P 500 Equal Weight ETF ($5.45 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($4.70 billion), Charter Communications, Inc. ($4.54 billion), and Industrial Select Sector SPDR Fund ($4.49 billion). View all of the most shorted stocks.

Short selling LSB is an investing strategy that aims to generate trading profit from Lakeshore Biopharma as its price is falling. LSB shares are trading down $0.04 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Lakeshore Biopharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of LSB, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including LSB, twice per month. The most recent reporting period available is May, 31 2025.